CN114271485A - Composition with blood sugar regulating effect and preparation method thereof - Google Patents
Composition with blood sugar regulating effect and preparation method thereof Download PDFInfo
- Publication number
- CN114271485A CN114271485A CN202111680058.1A CN202111680058A CN114271485A CN 114271485 A CN114271485 A CN 114271485A CN 202111680058 A CN202111680058 A CN 202111680058A CN 114271485 A CN114271485 A CN 114271485A
- Authority
- CN
- China
- Prior art keywords
- powder
- vitamin
- blood sugar
- preparation
- raw materials
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 40
- 239000008280 blood Substances 0.000 title claims abstract description 40
- 235000000346 sugar Nutrition 0.000 title claims abstract description 37
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 19
- 239000000203 mixture Substances 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000000843 powder Substances 0.000 claims abstract description 128
- 230000000694 effects Effects 0.000 claims abstract description 20
- 239000002775 capsule Substances 0.000 claims abstract description 18
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 235000013312 flour Nutrition 0.000 claims abstract description 10
- 238000002156 mixing Methods 0.000 claims abstract description 10
- 244000068988 Glycine max Species 0.000 claims abstract description 9
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 9
- 244000299461 Theobroma cacao Species 0.000 claims abstract description 9
- 235000009470 Theobroma cacao Nutrition 0.000 claims abstract description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 8
- 244000144725 Amygdalus communis Species 0.000 claims abstract description 8
- 235000011437 Amygdalus communis Nutrition 0.000 claims abstract description 8
- 241000186016 Bifidobacterium bifidum Species 0.000 claims abstract description 8
- 235000002722 Dioscorea batatas Nutrition 0.000 claims abstract description 8
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims abstract description 8
- 240000001811 Dioscorea oppositifolia Species 0.000 claims abstract description 8
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims abstract description 8
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 8
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 8
- 229920002752 Konjac Polymers 0.000 claims abstract description 8
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 8
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 8
- 241000194020 Streptococcus thermophilus Species 0.000 claims abstract description 8
- 235000020224 almond Nutrition 0.000 claims abstract description 8
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims abstract description 8
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 8
- 240000002900 Arthrospira platensis Species 0.000 claims abstract description 7
- 235000016425 Arthrospira platensis Nutrition 0.000 claims abstract description 7
- 235000013336 milk Nutrition 0.000 claims abstract description 7
- 239000008267 milk Substances 0.000 claims abstract description 7
- 210000004080 milk Anatomy 0.000 claims abstract description 7
- 229940082787 spirulina Drugs 0.000 claims abstract description 7
- 235000015099 wheat brans Nutrition 0.000 claims abstract description 7
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 6
- 108010011485 Aspartame Proteins 0.000 claims abstract description 6
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims abstract description 6
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims abstract description 6
- 229960003438 aspartame Drugs 0.000 claims abstract description 6
- 235000010357 aspartame Nutrition 0.000 claims abstract description 6
- 239000000605 aspartame Substances 0.000 claims abstract description 6
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 6
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims abstract description 6
- 239000004222 ferrous gluconate Substances 0.000 claims abstract description 6
- 235000013924 ferrous gluconate Nutrition 0.000 claims abstract description 6
- 229960001645 ferrous gluconate Drugs 0.000 claims abstract description 6
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 claims abstract description 6
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 6
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 6
- 239000000661 sodium alginate Substances 0.000 claims abstract description 6
- 229960001471 sodium selenite Drugs 0.000 claims abstract description 6
- 239000011781 sodium selenite Substances 0.000 claims abstract description 6
- 235000015921 sodium selenite Nutrition 0.000 claims abstract description 6
- 239000011716 vitamin B2 Substances 0.000 claims abstract description 6
- 239000011675 vitamin B5 Substances 0.000 claims abstract description 6
- 239000011670 zinc gluconate Substances 0.000 claims abstract description 6
- 235000011478 zinc gluconate Nutrition 0.000 claims abstract description 6
- 229960000306 zinc gluconate Drugs 0.000 claims abstract description 6
- 238000007873 sieving Methods 0.000 claims abstract description 5
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000012141 vanillin Nutrition 0.000 claims abstract description 5
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229930003270 Vitamin B Natural products 0.000 claims abstract description 4
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 4
- 230000001954 sterilising effect Effects 0.000 claims abstract description 4
- 239000011719 vitamin A Substances 0.000 claims abstract description 4
- 239000011720 vitamin B Substances 0.000 claims abstract description 4
- 235000019156 vitamin B Nutrition 0.000 claims abstract description 4
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 4
- 239000011709 vitamin E Substances 0.000 claims abstract description 4
- 229940046009 vitamin E Drugs 0.000 claims abstract description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 3
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract description 3
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims abstract description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 3
- 229940010454 licorice Drugs 0.000 claims abstract description 3
- 235000019155 vitamin A Nutrition 0.000 claims abstract description 3
- 239000011691 vitamin B1 Substances 0.000 claims abstract description 3
- 229940045997 vitamin a Drugs 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 10
- 239000008103 glucose Substances 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 7
- 239000011782 vitamin Substances 0.000 claims description 6
- 229930003231 vitamin Natural products 0.000 claims description 6
- 235000013343 vitamin Nutrition 0.000 claims description 6
- 229940088594 vitamin Drugs 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 5
- 235000011477 liquorice Nutrition 0.000 claims description 5
- 239000011715 vitamin B12 Substances 0.000 claims description 5
- 235000010485 konjac Nutrition 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 235000019634 flavors Nutrition 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 229940117960 vanillin Drugs 0.000 claims description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims 1
- 235000013305 food Nutrition 0.000 abstract description 14
- 239000000047 product Substances 0.000 abstract description 11
- 235000016709 nutrition Nutrition 0.000 abstract description 7
- 230000035764 nutrition Effects 0.000 abstract description 7
- 235000012631 food intake Nutrition 0.000 abstract description 6
- 238000001723 curing Methods 0.000 abstract description 3
- 239000013589 supplement Substances 0.000 abstract description 2
- 238000004659 sterilization and disinfection Methods 0.000 abstract 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 26
- 241000699670 Mus sp. Species 0.000 description 15
- 206010012601 diabetes mellitus Diseases 0.000 description 15
- 102000004877 Insulin Human genes 0.000 description 13
- 108090001061 Insulin Proteins 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 229940125396 insulin Drugs 0.000 description 13
- 241000282414 Homo sapiens Species 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 235000012054 meals Nutrition 0.000 description 10
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 10
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 9
- 239000008187 granular material Substances 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 239000006041 probiotic Substances 0.000 description 8
- 235000018291 probiotics Nutrition 0.000 description 8
- 230000001603 reducing effect Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 230000006870 function Effects 0.000 description 7
- 230000002218 hypoglycaemic effect Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 108091005995 glycated hemoglobin Proteins 0.000 description 6
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 5
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 229920002527 Glycogen Polymers 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 206010022489 Insulin Resistance Diseases 0.000 description 4
- 208000031971 Yin Deficiency Diseases 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000035622 drinking Effects 0.000 description 4
- 229940096919 glycogen Drugs 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 229940126673 western medicines Drugs 0.000 description 4
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 3
- 102000013009 Pyruvate Kinase Human genes 0.000 description 3
- 108020005115 Pyruvate Kinase Proteins 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 230000027939 micturition Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000001502 supplementing effect Effects 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000031975 Yang Deficiency Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 208000018914 glucose metabolism disease Diseases 0.000 description 2
- 230000034659 glycolysis Effects 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 235000019627 satiety Nutrition 0.000 description 2
- 230000036186 satiety Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 208000000857 Hepatic Insufficiency Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000029091 Refraction disease Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004430 ametropia Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 208000003611 congenital autoimmune diabetes mellitus Diseases 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 235000004879 dioscorea Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000062 effect on obesity Effects 0.000 description 1
- 230000009275 effect on visceral organ Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960003284 iron Drugs 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 208000006132 lipodystrophy Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229930029653 phosphoenolpyruvate Natural products 0.000 description 1
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 208000014733 refractive error Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 230000007651 self-proliferation Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 208000011726 slow pulse Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
A composition with the function of regulating blood sugar and a preparation method thereof, wherein A powder is prepared from the following raw materials in parts by weight: soybean flour 350, milk powder 250, cocoa powder 200, wheat bran 33.5, calcium carbonate 30, Chinese yam 25, spirulina powder 20, almond 20, dark plum 20, konjaku flour 20, licorice 10, sodium alginate 10, vanillin 4.5, ferrous gluconate 1.04, zinc gluconate 0.8, aspartame 0.3, vitamin B50.1, 0.1 of vitamin E, and vitamin B10.01, vitamin B20.01, 0.01 of vitamin A, 0.002 of sodium selenite and 120.00002 of vitamin B; the powder B is prepared from the following raw materials in percentage by weight: 80% of bifidobacterium bifidum powder, 10% of lactobacillus acidophilus powder and 10% of streptococcus thermophilus powder. The raw materials are respectively weighed according to the formula amount, the powder preparation and the soybean powder are put into an oven for curing, sterilization, sieving and mixing, the powder A is bagged, the powder B is a capsule and the capsules are respectively packaged into a complete set of products, and the composition can supplement nutrition, reduce the food consumption and improve the effect of regulating blood sugar by food.
Description
Technical Field
The invention relates to a composition with the function of regulating blood sugar, belonging to food with specific health care function.
Background
The etiology of diabetes is very complex, and many complications are serious, and the current main treatment method is to use medicines to control blood sugar. The hypoglycemic medicine is orally taken or injected with insulin. Insulin injections have side effects, and common side effects include hypoglycemia, anaphylaxis, lipodystrophy at the injection site, edema, ametropia, weight gain, etc. Where hypoglycemia is primarily associated with insulin dosage, which may occur if insulin is overdosed. There are many oral hypoglycemic drugs, some of which are not suitable for patients with contraindications, such as renal insufficiency, hepatic insufficiency, gastrointestinal reaction, etc. In addition, the method of taking the medicine also has contraindications and influences the efficacy of the medicine. Therefore, the medication needs to be controlled to be used and used according to the change of blood sugar. However, it is troublesome for the patient to accurately grasp the blood sugar changes. And food hypoglycemic method, such as selecting food, fruit, vegetable, tea, etc. The hypoglycemic effect is mainly because the hypoglycemic index is low and safe, but the hypoglycemic effect is slow. Yuan Siamese powder (original name Tian Sanqi tablet, sugar Qi Chong ji) is a product for regulating blood sugar by food, is a prior generation product of the applicant, reduces the drinking amount by supplementing nutrition and reduces the weight to control the blood sugar, is a health care food, has an auxiliary effect on controlling the increase of the blood sugar, and often causes people to have uncomfortable feelings such as dyspepsia and the like. The absorption is not smooth, so the effect is slow and not good. How to improve the effect of regulating blood sugar by food and improve the resistance to diabetes is a subject of continuous research and development of the inventors.
Disclosure of Invention
The purpose of the invention is: a composition having blood sugar regulating effect and its preparation method are provided, which can supplement nutrition, reduce food consumption, and improve blood sugar regulating effect of food.
The technical scheme of the invention is as follows: a composition with the effect of regulating blood sugar comprises powder A and powder B, wherein the powder A is prepared from the following raw materials in parts by weight:
(1) soybean flour 350, (2) milk powder 250, (3) cocoa powder 200, (4) wheat bran 38.12, (5) calcium carbonate 30, (6) Chinese yam 25, (7) spirulina powder 20, (8) almond 20, (9) dark plum 20, (10) konjaku flour 20, (11) licorice 10, (12) sodium alginate 10, (13) vanillin 4.5, (14) ferrous gluconate 1.04, (15) zinc gluconate 0.8, (16) aspartame powder 0.3, (17) vitamin B50.1, (18) vitamin E0.1, (19) vitamin B10.01, (20) vitamin B20.01, (21) vitamin A0.01, (22) sodium selenite 0.002, (23) vitamin B120.00002；
The powder B is prepared from the following raw materials in parts by weight:
bifidobacterium bifidum powder 28, lactobacillus acidophilus powder 3.5 and streptococcus thermophilus powder 3.5;
a method of making the composition:
1) preparation of powder A
Weighing Chinese yam, almond, dark plum, liquorice and wheat bran according to a formula proportion, respectively crushing, sieving and sterilizing for later use;
secondly, placing the soybean flour with the formula amount in an oven for curing at the temperature of 100-110 ℃ to remove beany flavor for later use;
thirdly, the konjak powder, the aspartame powder, the milk powder, the ferrous gluconate, the cocoa powder, the zinc gluconate, the calcium carbonate, the spirulina powder and the sodium alginate in the formula amount are respectively sieved for later use.
Mixing the materials to prepare a mixed material;
fifthly, the vitamin B is weighed according to the formula amount1Vitamin B2Vitamin B5Vitamin B12Adding vitamin A, vitamin E, sodium selenite and vanillin into the mixture, mixing uniformly, and subpackaging into powder A bags 30g each;
2) preparation of powder B
Weighing Bifidobacterium bifidum powder, Lactobacillus acidophilus powder and Streptococcus thermophilus powder in proportion, mixing, and subpackaging into powder B capsules, each capsule being filled with 0.35 g;
3) and packaging the powder bag A and the powder capsule B in a complete set.
The eating method and the eating amount are as follows:
a powder bag: the food is taken 1.5 hours before the middle meal and the evening meal, and the food is taken 30g in two bags each day.
And B, powder capsule: 6 granules are taken every day, each granule is filled with 0.35g, and the granules are eaten together with the powder A.
The trade name of the powder A is as follows: siamese powder, Tiansanqi tablet, glucose tablet; the trade name of the powder B is as follows: tiansanqi changle capsule.
The diet structure and the food intake of patients with diabetes are controlled first. The invention A powder (Tiansanqi Siamese powder, original Tiansanqi Xiaotangqi granule) is mainly prepared from soybean powder, milk powder, cocoa powder, konjak powder, wheat bran, spirulina powder and the like as main raw materials, Chinese medicinal components such as Chinese yam, dark plum, almond, liquorice and the like are added, and the powder is orally taken before meals, and is used for pertinently supplementing high protein, trace elements, zinc, selenium, iron, calcium and vitamins according to the nutritional status of a diabetic patient after controlling the dietary structure and the intake amount of the diabetic patient and various nutrients lacked in the body; the Chinese yam, the dark plum, the almond, the liquorice and the like regulate the functions of the spleen and the stomach, so that symptoms such as malnutrition and the like can not appear even if the food consumption is reduced, and the aim of regulating the blood sugar is fulfilled. The B powder (Tiansanqichangle capsule) is a micro-ecological preparation, consists of bifidobacterium bifidum, lactobacillus acidophilus and streptococcus thermophilus, and has the health-care functions of improving the gastrointestinal tract function and regulating the intestinal flora. The powder B enters the intestinal tract of a human body, firstly, components in the powder A are converted into small molecules from macromolecules through the powder B (probiotics), so that the absorption by the human body is easy, and the blood sugar reducing effect of the powder A (Siamese powder) is improved; secondly, the cocoa powder, the konjaku flour, the yam, the dark plum and other substances are rich in active polysaccharide, oligosaccharide, organic acid and other substances, and the probiotics carry out digestion, decomposition and conversion processes on the substances, and meanwhile, the probiotics are beneficial to the self proliferation and restore the micro-ecological balance of the organism. Thirdly, the probiotics control the growth and reproduction of harmful bacteria, improve the autoimmune capability and increase the target efficacy by improving the biological balance of intestinal flora. Fourthly, the taken probiotics participate in the energy metabolism of the human body, decompose some toxic and harmful substances in the human body and provide a plurality of vitamins, essential amino acids and polypeptides for the human body. The researchers found through animal experiments that the probiotics can effectively reduce blood sugar, plasma total cholesterol, low-density lipoprotein and the like, thereby assisting Siamese powder to improve a plurality of inducing factors of type II diabetes. The powder A and the powder B are matched, and the functions are as follows: the soybean powder, the cocoa powder and the like in the powder A have an expansion effect in the digestion process of a human body, so that the stomach has obvious satiety, the ingestion of other foods can be reduced, and the powder A is orally taken before meals, so that the food consumption is effectively controlled, and the hunger feeling is avoided; meanwhile, the powder B is orally taken, and after probiotics in the powder B are activated in the stomach for a period of time, the satiety effect generated by food and the powder A after eating is converted into nutrition which is easy to be absorbed by human bodies, so that the powder A and the powder B are taken together before eating, the purposes of reducing the food consumption, reducing the weight to control the blood sugar, supplementing the nutrition, avoiding the phenomena of dyspepsia and the like are realized. The combination of the powder A and the powder B improves the effects of A, B in regulating blood sugar, reducing blood fat and reducing weight of obese people, thereby improving the aims of insulin deficiency and insulin resistance. The results of mouse tests show that the product of the invention has no toxic side effect on the viscera of the mouse, and has certain improvement effect on the symptoms of obesity, polydipsia, drinking water, hyperglycemia, hyperlipidemia and the like of the diabetic mouse.
Traditional Chinese medicine holds that the essence of all diseases of human beings is yin-yang imbalance, and the same is true of diabetes. In clinical practice, it is appreciated that type II diabetes is mainly of deficiency syndrome, and even with excess syndrome, it is also of deficiency origin and excess origin. "Yin Ping Yang Mi and Shen Zhi Qiang", which is the final result of health and recovery from diseases, is emphasized by Huangdi's classic. The balance is achieved by coordinating yin and yang and coordinating mutually. The probiotics in the formula B has the functions of assisting human body nutrition metabolism, immunoregulation and the like, is used together with the Siamese powder A to maintain the human body nutrition balance, thereby improving the effects of regulating the dietary structure, reducing the weight and regulating the blood sugar, and fully playing the role of 'enabling the yang to be in the shade'. The regulation results of the traditional Chinese medicine between groups based on syndrome differentiation and typing are not different, and the regulation method is verified to have a positive two-way regulation effect on the yin-yang imbalance state of type II diabetes.
Detailed Description
Example 1
A composition with blood sugar regulating effect comprises powder A and powder B, wherein the powder A is prepared from the following raw materials: (23 raw materials in total, 1000g)
The powder B is prepared from the following raw materials:
bifidobacterium bifidum powder 28g Lactobacillus acidophilus powder 3.5 g; the total content of Streptococcus thermophilus powder 3.5g is 35g
The powder A is also named as: siamese powder (original name Tian Sanqi tablet comprising glucose control granules); the powder B is named as Tiansanqi Changle capsule.
A method of making the composition:
1) preparation of powder A
Weighing Chinese yam, almond, dark plum and liquorice and wheat bran according to a production formula, respectively crushing, sieving and sterilizing for later use;
secondly, placing the soybean flour with the formula amount in an oven for curing at the temperature of 100-110 ℃ to remove beany flavor for later use;
and thirdly, sieving the konjak powder, the aspartame, the milk powder, the ferrous gluconate, the cocoa powder, the zinc gluconate, the calcium carbonate, the spirulina powder and the sodium alginate according to the formula ratio respectively for later use.
Mixing the materials to prepare a mixed material;
fifthly, the vitamin B is weighed according to the formula amount1Vitamin B2Vitamin B5Vitamin B12Vitamin A, vitamin E, sodium selenite and vanillaAdding the extract into the mixed materials, uniformly mixing, and subpackaging into powder A bags, wherein each bag contains 30g of the extract;
2) preparation of powder B
Weighing Bifidobacterium bifidum powder, Lactobacillus acidophilus powder and Streptococcus thermophilus powder in proportion, mixing, and subpackaging into powder B capsules each of which is 0.35 g;
3) and packaging the powder A bag and the powder B capsule respectively. The product is sold and used in a set.
The eating method and the eating amount are as follows:
a powder bag: the food is taken 1.5 hours before the middle meal and the evening meal, and the food is taken 30g in two bags each day.
And B, powder capsule: 6 granules are taken every day, each granule is filled with 0.35g, and the granules are eaten together with the powder A.
The experimental report is as follows:
the conclusion of a research on the treatment effect of a Tiansanqi product on a type II diabetes model mouse is published in an important laboratory of the department of enzyme engineering education of the university of Life sciences college of Jilin, 4 Ri Jilin, 8 months and 2021: the experimental result shows that the Tiansanqi product can reduce the weight growth speed of db/db mice to a certain extent, reduce the fasting blood glucose value of the mice, relieve the increase of diet and drinking water of the mice caused by diabetes, improve the diabetes symptoms of the mice and has no toxic or side effect on visceral organs of the mice. The results of the mouse glucose tolerance experiment show that the Tian Sanqi administration has no obvious effect of reducing the peak value of blood sugar, and the Tian Sanqi high-dose group can reduce the blood sugar value (P <0.05) of the mouse after intragastric glucose administration and accelerate the serum glucose metabolism of the mouse. The level of glycated hemoglobin in the blood can reflect the glycemic control of the patient over 8-12 weeks. The glycosylated hemoglobin level of the model group db/db mouse is extremely high, after 8 weeks of administration of Tian Sanqi products, the glycosylated hemoglobin level in the blood of the mouse is extremely remarkably reduced (P <0.001), and the model group db/db mouse generates insulin resistance, beta cells secrete and release more insulin, so that hyperinsulinemia is caused, glucose metabolism disorder is presented, and vicious circle with insufficient beta cell function is caused. Improve insulin resistance and achieve the good effect of reducing blood sugar. After 8 weeks of administration of the high-dose group, the serum insulin level of the mice was reduced by 40.1% (P <0.001), after 8 weeks of administration of the medium-dose group, by 31.2% (P <0.001), and after 8 weeks of administration of the low-dose group, by 24.1% (P <0.001), as compared with the model group. Pyruvate kinase is one of the major rate-limiting enzymes in glycolysis, catalyzes phosphoenolpyruvate to generate ATP, and plays an important role in glucose metabolism. Compared with normal mice, the serum pyruvate kinase level of db/db mice is obviously reduced, and the glycolysis process of the body is seriously inhibited. After 8 weeks of administration, the serum pyruvate kinase levels increased by 70.2% (P <0.001) in the mice of the three-odd high dose group. Glycogen synthase kinase-3 (GSK-3) is a multifunctional serine/threonine kinase ubiquitous in eukaryotes and plays an important role in sugar metabolism. Meanwhile, GSK-3 remarkably increases the insulin resistance of the body and is a generally accepted target for treating diabetes at present. In this study, serum glycogen synthase kinase-3 levels were significantly elevated in db/db mice. After 8 weeks of administration, serum glycogen synthase kinase-3 levels were reduced by 34.0% (P <0.001) in the thirty-third high dose group mice compared to the model group. The experimental results show that the abnormal increase of the levels of hepatic glycogen and muscle glycogen of the model group db/db mice is probably caused by excessive eating and glucose metabolism disorder. After 8 weeks of administration, the liver glycogen and myoglycogen of the mice in the treatment group are obviously reduced on average (P <0.01), and the liver glycogen and myoglycogen levels are close to those of normal mice. Hyperglycemia, hypertension and hyperlipidemia become common pathological phenomena in clinical diabetes at present. Diabetic patients often have symptoms of lipid metabolism disorder, and hyperlipidemia is one of the important factors in the development of diabetic nephropathy [15 ]. In the study, compared with a blank group of mice, the serum total cholesterol level, triglyceride level and density lipoprotein cholesterol level of a db/db mouse model group are obviously increased (P is less than 0.001), and the lipid metabolism of a mouse body is disordered. After 8 weeks of administration, the total cholesterol level, triglyceride level and density lipoprotein cholesterol level in blood serum of each treatment group are remarkably reduced (P is less than 0.001), wherein the total cholesterol level of the Tian Sanqi medium dosage group is reduced by 37.5%, the triglyceride level is reduced by 37.2%, and the high density lipoprotein cholesterol is reduced by 35.7%. As a congenital diabetes model, the development process of db/db mouse is similar to that of human type II diabetes, and the diabetic nephritis complications are easy to occur due to a large number of microvascular complications [16 ]. In the experiment, a db/db mouse model is adopted to investigate the treatment effect of the Tiansanqi product on the type II diabetes, and the result shows that the Tiansanqi product has certain improvement effect on obesity, multiple drinking and drinking, hyperglycemia and hyperlipidemia of the diabetes mouse.
The beneficial effects of the present invention are illustrated by clinical observations below.
Clinical data
The subject group of the invention is under the coordination of Jilin medical college, Jilin province Chinese medicine academy, Changchun city Chinese medicine institute, Jilin province people hospital, Changchun Chinese medicine university, 3 months to 2015-4 months in 2015, 52 cases of II type diabetes mellitus are randomly adjusted in clinic according to the diagnosis sequence, wherein 34 cases of men, 18 cases of women, 45-75 years old, 51 years old on average, 6 months to 8 years old and 3 years old, 25 cases of qi-yin deficiency type (weakness and fatigue, frequent micturition, drinking urine, red face, soreness and weakness of waist and knees, dry throat and dry mouth, cold limbs, pale tongue with white fur and deep and thready weak pulse) are differentiated according to the diagnosis of traditional Chinese medicine; qi deficiency type 10 cases (debilitation, spontaneous perspiration, pale complexion, numbness of limbs, frequent micturition, loose stool, white fur, and weak pulse); yin deficiency type 10 cases (feverish sensation in the palms, soles and chest, dry mouth, polydipsia, night sweat, hunger, frequent micturition, turbid urine, red tongue with little coating, deep, thready and rapid pulse); yang deficiency type 7 cases (aversion to cold, cold limbs, weakness of feet and knees, lassitude, pale tongue with white coating, slow pulse and weak pulse). Blood glucose before meal (normal value 4.0-6.1mmol/L, 6 cases > 15mmol/L, 14 cases > 10mmol/L, 17 cases > 8mmol/L, 15 cases > 6.1 mmol/L; glycated hemoglobin (normal < 6.1mg/dl) > 9mg/dl in 5 cases, > 8mg/dl in 10 cases, > 7mg/dl in 19 cases, > 6.1mg/dl in 18 cases, with an average of 7.5 + -1.05 mg/dl; 34 cases of patients with blood sugar control by oral administration, 12 cases of patients with insulin injection and 6 cases of patients with oral administration and injection.
Method of regulation
Regulating the initial stage, continuously using oral western medicines or insulin injection in the whole medical record group, and taking Jiaole capsule 2 times a day, 3 granules each time 30 minutes to 1.5 hours before meal; taking 30g of glucose tablet 1.5 hours before meal 2 times a day. The blood sugar before meal is monitored every 10 days, the dosage of western medicine for oral administration and insulin for injection is adjusted, and the dosage of Changle capsule and glucose snack is not changed. 3 months is a treatment course, and after two treatment courses, glycosylated hemoglobin is detected and a case is made.
Regulating result
After 1 month of regulation, 11 cases of blood sugar details in the whole group are reduced (the mean value of blood sugar is reduced after more than 3 times of monitoring is reduced) by more than 1.5 mmol/L), the reduction of oral western medicines and insulin injection is started, and after 2 months, 18 cases of blood sugar details are reduced; after one treatment course, the blood sugar level of 25 cases is reduced, the blood sugar of 11 cases reaches the normal value, 8 cases stop taking the western medicines orally, and 2 cases stop injecting insulin. After two treatment courses, the blood sugar level of 44 cases is reduced (84.6%); normal for 25 sugars, (48%); 15 cases stop using western medicines, or insulin; 35 cases (67.3%) of glycated hemoglobin had decreased index, 8 cases (15.4%) of glycated hemoglobin had reached normal value, and the mean glycated hemoglobin was 6.9. + -. 1.03mg/dl, and the comparative difference between before and after adjustment was statistically significant (P < 0.05). After two courses of treatment are adjusted, the clinical symptoms of each group are improved according to syndrome differentiation of the traditional Chinese medicine. Index reduction of blood glucose and glycated hemoglobin: 21 cases of qi-yin deficiency, 8 cases of qi-deficiency, 9 cases of yin-deficiency, and 6 cases of yang-deficiency. The regulation results between the types have no statistical significance (P > 0.05). The Tiansanqi product is proved by human body tests to be safe to eat and free from toxic and side effects.
Claims (2)
1. The composition with the effect of regulating blood sugar is characterized by consisting of powder A and powder B, wherein the powder A is prepared from the following raw materials in parts by weight:
(1) soybean flour 350, (2) milk powder 250, (3) cocoa powder 200, (4) wheat bran 38.12, (5) calcium carbonate 30, (6) Chinese yam 25, (7) spirulina powder 20, (8) almond 20, (9) dark plum 20, (10) konjaku flour 20, (11) licorice 10, (12) sodium alginate 10, (13) vanillin 4.5, (14) ferrous gluconate 1.04, (15) zinc gluconate 0.8, (16) aspartame powder 0.3, (17) vitamin B50.1, (18) vitamin E0.1, (19) vitamin B10.01, (20) vitamin B20.01, (21) vitamin A0.01, (22) sodium selenite 0.002, (23) vitamin B12 0.00002；
The powder B is prepared from the following raw materials in parts by weight:
bifidobacterium bifidum powder 28, lactobacillus acidophilus powder 3.5 and streptococcus thermophilus powder 3.5;
the trade name of the powder A is as follows: siamese powder, Tiansanqi tablet, glucose tablet; the trade name of the powder B is as follows: tiansanqi changle capsule.
2. A process for preparing the composition of claim 1: the method is characterized in that:
1) preparation of powder A
Weighing Chinese yam, almond, dark plum, liquorice and wheat bran according to a formula proportion, respectively crushing, sieving and sterilizing for later use;
secondly, placing the soybean flour with the formula amount in an oven for curing at the temperature of 100-110 ℃ to remove beany flavor for later use;
thirdly, the konjak powder, the aspartame powder, the milk powder, the ferrous gluconate, the cocoa powder, the zinc gluconate, the calcium carbonate, the spirulina powder and the sodium alginate in the formula amount are respectively sieved for later use.
Mixing the materials to prepare a mixed material;
fifthly, the vitamin B is weighed according to the formula amount1Vitamin B2Vitamin B5Vitamin B12Adding vitamin A, vitamin E, sodium selenite and vanillin into the mixture, mixing uniformly, and subpackaging into powder A bags 30g each;
2) preparation of powder B
Weighing Bifidobacterium bifidum powder, Lactobacillus acidophilus powder and Streptococcus thermophilus powder in proportion, mixing, and subpackaging into powder B capsules, each capsule being filled with 0.35 g;
3) and packaging the powder bag A and the powder capsule B in a complete set.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111680058.1A CN114271485A (en) | 2021-12-31 | 2021-12-31 | Composition with blood sugar regulating effect and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111680058.1A CN114271485A (en) | 2021-12-31 | 2021-12-31 | Composition with blood sugar regulating effect and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114271485A true CN114271485A (en) | 2022-04-05 |
Family
ID=80879889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111680058.1A Pending CN114271485A (en) | 2021-12-31 | 2021-12-31 | Composition with blood sugar regulating effect and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114271485A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107260785A (en) * | 2017-07-28 | 2017-10-20 | 吉林天三奇药业有限公司 | Traditional Chinese medicine probiotic powder, preparation method thereof |
| CN108523138A (en) * | 2017-03-02 | 2018-09-14 | 劲膳美食品股份有限公司 | A kind of hypoglycemic meal replacement powder |
-
2021
- 2021-12-31 CN CN202111680058.1A patent/CN114271485A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108523138A (en) * | 2017-03-02 | 2018-09-14 | 劲膳美食品股份有限公司 | A kind of hypoglycemic meal replacement powder |
| CN107260785A (en) * | 2017-07-28 | 2017-10-20 | 吉林天三奇药业有限公司 | Traditional Chinese medicine probiotic powder, preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 刘长江等: "益生菌加洚糖奇非药物调节2型糖尿病52例临床观察", 中国社区医师, vol. 32, no. 06, pages 127 * |
| 嫩江华宇信息平台: "请您相信天三奇能给你带来健康的家庭！", 《微信搜索》, pages 4 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105029407A (en) | Medical formula food for inflammatory bowel disease | |
| CN104187708A (en) | Total-nutrient formulated food for patients with diabetes | |
| CN104855967A (en) | Non-whole nutrient formula food for patients having obesity or fat-reducing surgery | |
| CN104187632A (en) | Total-nutrient formulated food eaten by patients with osteoporosis | |
| CN104161263B (en) | The full nutritional formulas of child | |
| CN104256648A (en) | Total-nutrient formula food for thyroid cancer | |
| CN111955720A (en) | Special postpartum lactation-promoting diet for puerpera and preparation method thereof | |
| CN105029393A (en) | Medical formula food for children | |
| CN104839684A (en) | Medical formula food for people with helicobacter pylori related gastritis | |
| CN105326038A (en) | Pregnant-woman pregnancy-vomiting total-nutrient formula food | |
| CN104839695A (en) | Inflammatory bowel disease non-total nutrient formula food | |
| CN104323240A (en) | Full-nutrition formula food for colorectal cancer | |
| CN105707378A (en) | Black-highland barley coffee with effect of slimming | |
| CN104161266A (en) | Total nutrient formula food for patients with deficiency cold of spleen and stomach | |
| CN104256656A (en) | Full-nutrition formulated food for fatty acid metabolic disorder | |
| CN108523123A (en) | A kind of full nutritional support food of diabetes | |
| CN109043555A (en) | A kind of Special food and preparation method thereof that hyperglycemic patients are edible | |
| CN109043554A (en) | A kind of Special food of high dietary-fiber and preparation method thereof | |
| CN105249441A (en) | Folium mori health care product for reducing blood glucose and preparation method thereof | |
| CN114271485A (en) | Composition with blood sugar regulating effect and preparation method thereof | |
| CN104839681A (en) | Medical formula food for people with damp heat constitution | |
| CN104323278A (en) | Full-nutrition formula food for liver cancer | |
| CN104146266A (en) | Fully nutrient formula food for recuperating chloasma | |
| CN106615515A (en) | Cordyceps militaris and selenoprotein pressed candy | |
| CN104256653A (en) | Leukemia total-nutrient formula food |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20220405 |